Home  |  Contact

UniProtKB/Swiss-Prot P13569: Variant p.Arg74Trp

Cystic fibrosis transmembrane conductance regulator
Gene: CFTR
Variant information

Variant position:  74
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Tryptophan (W) at position 74 (R74W, p.Arg74Trp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to large size and aromatic (W)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CF and CBAVD.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  74
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1480
The length of the canonical sequence.

Location on the sequence:   EREWDRELASKKNPKLINAL  R RCFFWRFMFYGIFLYLGEVT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         EREWDRELAS-KKNPKLINALRRCFFWRFMFYGIFLYLGEVT

Gorilla                       EREWDRELAS-KKNPKLINALRRCFFWRFMFYGIFLYLGEV

                              EREWDRELAS-KKNPKLINALRRCFFWRFAFYGILLYLGEV

Rhesus macaque                EREWDRELAS-KKNPKLINALRRCFFWRFMFYGILLYLGEV

Chimpanzee                    EREWDRELAS-KKNPKLINALRRCFFWRFMFYGIFLYLGEV

Mouse                         EREWDREQAS-KKNPQLIHALRRCFFWRFLFYGILLYLGEV

Rat                           EREWDREQAS-KKKPQLIHALRRCFVWRFVFYGVLLYLGEV

Pig                           EREWDRELAS-KKNPKLINALRRCFFWRFMFYGIILYLGEV

Bovine                        EREWDRELAS-KKNPKLINALRRCFFWRFMFYGIILYLGEV

Rabbit                        EREWDRELAS-KKKPKLINALRRCFFWRFMFYGILLYLGEV

Sheep                         EREWDRELAS-KKNPKLINALRRCFFWRFMFYGIILYLGEV

Horse                         EREWDRELVS-KKNPKLINALRRCFFWRFMFYGIILYLGEV

Xenopus laevis                EREWDREVATSKKNPKLINALKRCFFWKFLFYGILLYLGEV

Zebrafish                     EKEWDREVASGKKKPSLLRAMARCYIKPFLLFGFLLYIGEA

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1480 Cystic fibrosis transmembrane conductance regulator
Topological domain 1 – 77 Cytoplasmic
Helix 69 – 96


Literature citations

Detection of cystic fibrosis transmembrane conductance regulator (CFTR) gene rearrangements enriches the mutation spectrum in congenital bilateral absence of the vas deferens and impacts on genetic counselling.
Ratbi I.; Legendre M.; Niel F.; Martin J.; Soufir J.C.; Izard V.; Costes B.; Costa C.; Goossens M.; Girodon E.;
Hum. Reprod. 22:1285-1291(2007)
Cited for: VARIANTS GLN-75 AND MET-470; VARIANTS CBAVD TRP-74; HIS-110; HIS-117; HIS-170; TRP-206; ASP-232; TRP-334; TYR-443; PHE-508 DEL; VAL-556; ILE-562; ALA-576; ASP-622; CYS-668; GLY-938; ILE-952; VAL-959; PHE-977; PHE-997; CYS-1032; ARG-1069; HIS-1152; GLU-1153; ASN-1270; 1282-TRP--LEU-1480 DEL; HIS-1352 AND 1473-GLU--LEU-1480 DEL;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.